"We are pleased to add Jake and Simos to the Regulus board. He holds an A.B. Rajeev (Raj) Shah is Managing Partner at RA Capital Management, LLC, a multi-stage investment manager dedicated to evidence-based investing in healthcare and life sciences, including companies developing novel drugs, medical devices, and diagnostics. Mr. Jackson holds a B.S. From 1999 to 2008, Kapil served at Hoffmann-La Roche, including as Vice President, Head, Oncology Disease Biology Leadership Team, and Head, Oncology Clinical Development, during which he led numerous drug approvals, including Herceptin®, Tarceva®, and Avastin®. Mr. Mathers is currently a partner at New Enterprise Associates, Inc., a global venture capital firm that invests in technology and healthcare companies, a position he has held since August 2008. Robert (Bob) A. Ingram serves as Chairman of the Board of Black Diamond Therapeutics. from the University of Pennsylvania School of Medicine, an M.B.A. from the Wharton School of the University of Pennsylvania, where he graduated with Honors and was a Palmer Scholar, and a B.S. January 7, 2021APL-106 (uproleselan) Granted Breakthrough Therapy Designation in China for the Treatment of Acute Myeloid Leukemia, December 7, 2020New Supportive Efficacy Data for GlycoMimetics’ Rivipansel in Sickle Cell Acute Vaso-Occlusive Crisis Presented at 62nd ASH Annual Meeting and Exposition, December 5, 2020GlycoMimetics’ Uproleselan in Combination With Venetoclax/HMA Shown to Break Chemoresistance, Reduce Tumor Burden and Increase Survival in AML Model, November 10, 2020GlycoMimetics to Present at Two Upcoming Virtual Healthcare Investor Conferences, © He has authored several publications in leading scientific and business journals. – General Partner, New Enterprise Associates Ali Behbahani, M.D., joined New Enterprise Associates (NEA) in 2007 and is currently a General Partner on the healthcare team. From 2008 to 2011, he served as a Venture Partner with New Enterprise Associates, Inc. (NEA), a venture capital firm, where he focused on consumer technology opportunities. He currently serves as a senior adviser to the health care team of New Enterprise Associates … Both NEA and Sarissa Capital participated in … Board of Directors Ali Behbahani, M.D. Prior to that, he served as Executive Vice President, Chief Financial Officer and Treasurer at Catalyst Health Solutions, a publicly held pharmacy benefit manager with over $5 billion in revenues. Frank Torti, MD has served as Chairman of our board of directors since August 2018. Ms. Grayson is a Managing Partner of Construct Capital, a venture capital firm she co-founded in 2020. Ms. degree from Dartmouth College and her M.B.A. from Harvard Business School. Dr. Torti joined Roivant from New Enterprise Associates (NEA), a leading venture capital firm where he served as partner. NEA Venture Partner brings three decades of experience scaling enterprise software companies to support DataRobot’s continued growth Boston, MA – June 3, 2019 – DataRobot, the leader in automated machine learning, today announced the addition of Hilarie Koplow-McAdams, Venture Partner at New Enterprise Associates (NEA), to its Board of Directors. He has also led three NEA-funded companies, serving as Chairman and CEO of Genetic Therapy, Inc., President and CEO of Life Technologies and President and CEO of Bethesda Research Labs. He specializes in biotechnology and works with members of NEA's healthcare investment group on medical devices and specialty pharmaceutical companies. Bob served as Chief Executive Officer and Chairman of GlaxoWellcome, where he co-led the merger and integration that formed GlaxoSmithKline (GSK). Before joining Novartis, Mrs. King spent 10 years with Genetic Therapy, Inc. through the company’s early stage, initial public offering and eventual sale to Novartis. Kapil founded KAPital Consulting, LLC, in 2008, a company dedicated to helping biotechnology, pharmaceutical, and diagnostic companies realize the clinical and commercial advances in oncology. and Ph.D. from Cornell University and his M.D. He remained at the NIH for 10 years, finally serving as a tenured research chemist. Dr. Torti has served as Vant Investment Chair of Roivant Pharma, a business unit of Roivant Sciences, since August 2018. LYZZ Capital, Board Member. RESTON, Va.—March 4, 2014—Appian, the market leader in modern business process managment (BPM) software, today announced that Harry Weller, General Partner at New Enterprise Associates (NEA), has joined Appian’s board of directors, in conjunction with the firm’s recent minority investment. in pharmacy from the Philadelphia College of Pharmacy and Science and an M.B.A. from the University of Notre Dame. from Harvard Medical School. Previously he served as Executive Vice President for Medical and Regulatory strategy and as the Senior Vice President of Medical and Regulatory Affairs at Synageva BioPharma Corp. Dr. Goldberg also worked in a variety of senior management positions at Genzyme Corporation, including as Senior Vice President and Therapeutic Group Head for Oncology and Personalized Genetic Health Clinical Development. Dr. Goldberg is a board-certified medical oncologist and hematologist and has more than 50 published papers. Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, has appointed Paul Walker to its board of directors, and Dr. Ali Behbahani as a board observer, effective February 6, 2020. Prior to NEA, he held positions at The Medicines Company, Morgan Stanley Venture Partners and Lehman Brothers. In 2013, he received the NACD B. Kenneth West Lifetime Achievement Award from the National Association of Corporate Directors. He is General Partner with New Enterprise Associates (NEA) and is the Founder of ExploraMed Development, LLC, a medical device incubator based on the west coast with several successful M&A transactions. His teams have progressed multiple novel agents through development in oncology, cardiovascular disease, and retinal degeneration. Chair of the Nominating and Governance Committee. Ali is a general partner at New Enterprise Associates (NEA). Previously, he helped co-found the U.S. subsidiary of BioCarb and became its international Vice President of Research. Mrs. King is co-founder and CEO of GlycoMimetics, Inc. (GMI). Garry serves on the Board of Directors of Stoke Therapeutics, Inc. Garry earned his Ph.D. from the University of Cambridge, where he studied the regulation of oncogenes in immune cells. He received a B.Sc. Mrs. King also worked previously at ALZA Corporation in Palo Alto, CA and at Bain & Company in Boston. Mr. Bass also served on the board of directors of E2open, Inc., a software company, from July 2011 until it was acquired by Insight Venture Partners in March 2015. The recipient of three presidential appointments, Bob was the Founding Chair of the CEO Roundtable on Cancer and currently serves as a member of the President’s Cancer Panel. Board of Directors. Mr. Pearson, a CPA, holds B.S. One Main Street, 10th Floor He was an associate professor of medicine at Harvard Medical School from 1996 to 2018 and he now serves as senior lecturer. Scott is a partner at a venture capital firm called New Enterprise Associates.Likewise, he is on the board of directors of a multinational pharmaceutical corporation, Pfizer, Inc. Prior to joining Versant, Brad served as Executive Vice President, Global Head of Business Development, Licensing & Alliances at Roche. Both bring a depth of experience that we believe will add significant value to our board and Company," said Stelios Papadopoulos, Ph.D., Chairman of the Board of Directors of Regulus.. Mr. Nunn is a venture advisor at New Enterprise Associates (NEA) and Dr. Simeonidis is a partner with Sarissa Capital. He earned an M.S. He serves as co-chair of the Scientific Advisory Board of the Institute for Bioscience and Biotechnology Research (IBBR) at the University of Maryland. Core Values. from Cornell University, where he majored in Chemistry. Under Mr. Jackson's leadership, Celator successfully developed Vyxeos® for treatment of newly diagnosed AML patients. Raj is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools. President, CEO, Board Member Terry Gould . He is also a member of the National Cancer Institute Experimental Therapeutics panel and a member of the New Drug Advisory Committee of the European Organisation for Research and Treatment of Cancer. Randy Alexander Independent Board Member. Present board memberships in addition to GlycoMimetics include Clovis Oncology, Proteostasis Therapeutics, and Senseonics. We are a global venture capital firm with a mission to make the world better by helping founders build great companies that improve the way we live, work and play. Trillium Therapeutics Announces Changes to Its Board of Directors. Edward T. Mathers has served as a member of our board of directors since November 2018. New York, NY 10014, 25 Health Sciences Drive, Suite 105 He previously served as President and CEO of ImmunoGen from 2009 until his retirement in May 2016, preceded by several executive roles including President, COO, Executive Vice President and CFO. Present board memberships in addition to … Before his appointment as Black Diamond’s President and CEO, David was Vice Dean, Innovation & Entrepreneurship, and Associate Professor in Cancer & Stem Cell Biology, at Duke-NUS Medical School, Singapore, where he founded and built Duke-NUS’s Centre for Technology & Development, which has developed a pipeline of innovation projects. He has more than 25 years of experience in building healthcare businesses and leading high-performing teams of professionals. Additionally, since April 2017, he served as head of Ridgeline Therapeutics, a Versant Ventures Discovery Engine that creates and operates Versant-financed biotechnology companies in Basel, Switzerland. UPDATE Dr. Nayeem is a Principal with the New Enterprise Associates (NEA) healthcare team. She also served as Chair of the Maryland Life Sciences Advisory Board under former Governor Martin O’Malley. Mrs. King is the past Chair of the Board as well as past of the Chair Emerging Companies Governing Board of the Biotechnology Innovation Organization (“BIO”); she continues to serve on BIO’s executive committee. Sam also serves as the Chairman of the Board of Directors of Casebia Therapeutics, a joint subsidiary formed by CRISPR and Bayer. Dr. Torti joined Roivant from New Enterprise Associates (NEA), a leading venture capital firm where he served as partner. His track record consists of successive outlier returns including Amira (sale), Okairos (sale), Speedel (sale), Quanticel (sale), Novira (sale), Flexion (2014 IPO), Crispr (2016 IPO), BioTie (sale), Jecure (sale), Inception (multiple sales), and Blue Rock (sale), and he continues to manage several other promising investments. From 2008 to 2011, he served as a Venture Partner with New Enterprise Associates, Inc. (NEA), a venture capital firm, where he focused on consumer technology opportunities. Strive Health names Rich Whitney to its Board of Directors. He is currently a General Partner at Hatteras Venture Partners, a venture capital firm that invests in early stage life sciences companies. He is also active in the firm’s outreach efforts, speaking frequently both at industry events and in classrooms. Alex has served as a Managing Director at Versant Ventures, a healthcare investment firm, since March 2020, and previously served as a Partner from January 2018 to February 2020 and as a Venture Partner from January 2017 to December 2017 at Versant Ventures. UPDATE Dr. Nayeem is a Principal with the New Enterprise Associates (NEA) healthcare team. Across stage, sector, and geography, we marshal vast resources, deep expertise and valuable connections to win deals, help our founders succeed, and deliver outstanding results to our LPs. Prior to joining Roche, he worked in the oncology clinical development group at Eli Lilly and Company. Prior to NEA, he held positions at The Medicines Company, Morgan Stanley Venture Partners and Lehman Brothers. David M. Epstein, Ph.D., is a biopharmaceutical leader and executive who has successfully led large and small R&D teams in academic, start-up, mid-size, and global large-pharmaceutical settings. Dr. Barrett joined venture capital firm New Enterprise Associates (NEA) in 2001 as a General Partner. Prior to Genzyme, he was a staff physician at Brigham and Women’s Hospital and Dana Farber Cancer Institute, where he still holds appointments. Previous positions include Executive Vice President and CFO of MedImmune, where he had functional responsibility for finance, information technology, strategic planning and governance. Prior to that, she was Executive Vice President and Chief Commercial Officer at Incyte, leading commercial operations for that company’s launch of first-in-class, first-in-disease oncology product Jakafi®. Prior to co-founding GMI, Dr. Magnani founded and led a predecessor company, GlycoTech Corporation, as its President and CEO. She now serves on the board of the University of Maryland BioPark. An industry leader with expertise in strategy and operations in biotech and a wide range of pioneering therapeutic technologies, Samarth (Sam) Kulkarni, Ph.D. currently serves as CEO of CRISPR Therapeutics AG. He formerly served as a Non-Executive Director of Adaptimmune Limited since September 2014, initially in a capacity as a nominee of New Enterprise Associates 14 LP (NEA), one of our shareholders. Before founding GMI, she was an Executive in Residence at New Enterprise Associates (NEA), one of the nation’s leading venture capital firms. Before joining ImmunoGen, Mr. Junius was Executive Vice President and CFO of New England Business Service, Inc. until its acquisition by Deluxe Corporation in 2004. Dr. Previously, Dr. Koenig served as Senior Vice President of Research at MedImmune, where he participated in the selection and maturation of its product pipeline. document.write(new Date().getFullYear()); Ali Behbahani, M.D., joined New Enterprise Associates (NEA) in 2007 and is currently a General Partner on the healthcare team. Dr. Koenig received his A.B. Paul Walker of New Enterprise Associates is appointed to the Board of Directors. . Dr. Makower has dedicated his life to the creation of medical technologies which improve the quality of life for patients. He is the recipient of the 2015 President’s Innovation Award from the Society of Glycobiology, has authored over 100 scientific publications and is an inventor on more than 90 issued patents. He specializes in biotechnology and works with members of NEA's healthcare investment group on medical devices and specialty pharmaceutical companies. He also developed fundamental technology for the identification of functional carbohydrate epitopes. We believe we’re better together, working as a team. Website Design & Development: Graphic Beans, Site Map | Terms of Use | Privacy | Contact Us, APL-106 (uproleselan) Granted Breakthrough Therapy Designation in China for the Treatment of Acute Myeloid Leukemia, New Supportive Efficacy Data for GlycoMimetics’ Rivipansel in Sickle Cell Acute Vaso-Occlusive Crisis Presented at 62nd ASH Annual Meeting and Exposition, GlycoMimetics’ Uproleselan in Combination With Venetoclax/HMA Shown to Break Chemoresistance, Reduce Tumor Burden and Increase Survival in AML Model, GlycoMimetics to Present at Two Upcoming Virtual Healthcare Investor Conferences. He also worked at the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, where he investigated the immune response to retroviruses and studied the pathogenesis of AIDS. in Business Administration from Eastern Illinois University. New Enterprise Associates, Board Member Kevin Li, PhD. Dr. Kapil Dhingra is an accomplished medical oncologist and pharmaceutical executive with a proven track record in academic research, patient care, and drug development. degrees in Business Administration from the University of Delaware and in Accounting from the University of Maryland University College, as well as an M.S. Prior to TCR2, Garry served as Chief Financial Officer at DaVita Healthcare and Chief Operating Officer at Regulus Therapeutics. Brad combines 13 years of global pharmaceutical industry experience and a similar tenure as a venture capitalist. Paul Walker of New Enterprise Associates is appointed to the Board of Directors. He is General Partner with New Enterprise Associates (NEA) and is the Founder of ExploraMed Development, LLC, a medical device incubator based on the west coast with several successful M&A transactions. Carol Gallagher, PharmD. Dr. Goldberg is a consultant to several biotechnology companies. Prior to joining Versant, from 2013 to 2016, Alex served as Vice President and Global Head of Medicinal Chemistry at F. Hoffmann-La Roche AG, a multinational healthcare company, and held various leadership positions at Roche in pharmaceutical drug discovery and medicinal chemistry across Europe, the U.S., and Asia. He specializes in investments in the biopharmaceutical, medical device, specialty pharmaceutical, and healthcare services sectors. from Harvard College and an M.D. New Enterprise Associates. Mr. Junius holds an undergraduate degree in Political Science from Boston College and a Master’s in Management from Northwestern University’s Kellogg School of Management. Board of Directors / Compensation Committee Informatica Mar 2014 - Aug ... Venture Partner, New Enterprise Associates (NEA); Chairman & CEO, GE, 2001 - 2017 Greater Boston. Dr. Magnani received his Ph.D. from Princeton University and then joined the Laboratory of Biological Pharmacology of the National Institute of Arthritis, Diabetes and Digestive and Kidney Diseases (NIADDK) of the National Institutes of Health (NIH). Mr. Junius has been a director of GlycoMimetics, Inc. since March 2016. Dr. Magnani is an expert in glycobiology, having discovered and characterized many carbohydrate tumor antigens, such as the FDA-approved cancer diagnostic, CA19-9. Mr. Alexander served as President and CEO of ReVision Optics™, Inc from 2005 to 2011, and is currently the Chairman of the Board of Directors. Tech. from Brown University. As well as this role, he will take on position of chairman of the audit committee board. CAMBRIDGE, Mass., Feb. 07, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that Paul Walker has been appointed to the Company’s Board of … Ms. Grayson has served as a member of our Board of Directors since October 2015. Mr. Pearson led the company’s financial activities, including performance management, investor relations, SEC compliance, capital strategy and planning, until the company was acquired by SXC Health Solutions (now Catamaran Corporation) in 2012. Alex Mayweg, Ph.D., has served as a member of our board of directors since March 2017 and, from March 2017 to September 2019, served as our interim Chief Scientific Officer. Corporate Headquarters Scott Jackson served as Celator CEO and as a member of the Board of Directors from April 2008 until July 2016, when the company was acquired by Jazz Pharmaceuticals plc. Previously, he was Chief Scientific Officer at OSI Pharmaceuticals, a pharmaceutical company acquired by Astellas Pharma, and founder of Archemix Corporation, where he led the advancement of multiple product candidates into the clinical in multiple therapeutic areas. He also worked in various divisions of SmithKline. Anderson Cancer Center and during his industry career maintained active faculty appointments at Indiana University School of Medicine and at Memorial Sloan Kettering Cancer Center in New York. in Chemistry from Boston College. He has more than 25 years of experience in the pharmaceutical and biotechnology industry and has held positions of increasing responsibility in sales, marketing and commercial development at Eli Lilly & Co., SmithKline Beecham, ImClone Systems Inc., Centocor Inc., a division of Johnson & Johnson, Eximias Pharmaceutical and YM BioSciences. Brad Bolzon, Ph.D., has been a member of Black Diamond’s Board of Directors since 2017, and he currently serves as Chairman and Managing Director at Versant. Her additional experience includes leadership positions at Pfizer, where her final role was Vice President and General Manager of the US Oncology Business Unit, and at Marine Midland/HSBC, where she was Vice President in corporate finance. Kevin Li, PhD. Board of Directors Dan Burgess . in Biomedical Engineering, Electrical Engineering and Chemistry from Duke University. RESTON, Va.— March 4, 2014— Appian, the market leader in modern business process management (BPM) software, today announced that Harry Weller, General Partner at New Enterprise Associates (NEA), has joined Appian’s board of directors, in conjunction with the firm’s recent minority investment. Stony Brook, NY 11790, 661 University Avenue Toronto, ON M5G 0B7 Canada. Randy is a seasoned senior medical device executive and leader in the ophthalmic industry. He also serves as director at IDEXX Laboratories, Inc. New Enterprise Associates. Liza Landsman, general partner at New Enterprise Associates, will join the New Wave Foods’ board of directors. Under his leadership, Roche established alliances with more than 75 venture-backed biotech companies worldwide and transformed its R&D pipeline into an industry leader. In addition, he was a consultant with Bain & Company. Desktop Metal, Burlington, Massachusetts, USA, has announced the appointment of Scott Dussault to its board of directors effective December 18, 2020. Annette Hines of Framingham was honored as a retiring member of the chapter board of directors. Ali is a general partner at New Enterprise Associates (NEA). Michael N. Dudley, PharmD. Dr. Magnani is co-founder and CSO of GlycoMimetics, Inc (GMI). Scott Gottlieb, M.D, is an American physician who worked as the 23rd Commissioner of the Food and Drug Administration (FDA).He served in the FDA from May 2017 until April 2019. Ms. Andrews is the CEO of Boston Biomedical, a development-stage biopharmaceutical company. Alex earned his Ph.D. in Organic Chemistry at Oxford University, followed by post-doctorate training at Stanford University. New Enterprise Associates, Board Member. He presently serves on the Board of Directors of MacroGenics, Inc. and the Board of Trustees of the Eastern Pennsylvania Chapter of The Leukemia and Lymphoma Society®. Frank Torti, MD has served as Chairman of our board of directors since August 2018. He joined CRISPR in 2015 in the early stages of the company as Chief Business Officer (CBO), and then served as President and CBO before being named its CEO in 2017. Company profile page for New Enterprise Associates Inc including stock price, company news, press releases, executives, board members, and contact information He received a Ph.D. in Bioengineering and Nanotechnology from the University of Washington and a B. He conducted basic science research in the fields of viral fusion inhibition and structural proteomics at the National Institutes of Health (NIH) and at Duke University. Prior to joining NEA, Ali worked as a consultant in business development at The Medicines Company, a specialty pharmaceutical company developing acute care cardiovascular products. . CAMBRIDGE, Mass., Feb. … His versatile career has included operational roles covering drug development, manufacturing, financing, licensing, and M&A. Prior to that, Brad held executive roles at Eli Lilly in drug discovery, clinical research, regulatory affairs and business development. Dr. Barrett holds a Ph.D. in biochemistry at the University of Tennessee, an M.B.A. from the University of Santa Clara, and a B.S. Mr. Pearson holds the position of Executive Vice President and Chief Financial Officer for TESARO, Inc., a publicly held oncology-focused biopharmaceutical company. and a Ph.D. in Pharmacology from the University of Toronto and conducted post-doctoral work at the University of Ottawa Health Institute. He completed his residency in internal medicine at Lincoln Medical and Mental Health Center and New York Medical College and completed his fellowship in hematology and oncology at Emory University School of Medicine. He also had global leadership roles in running the biotechnology practices at Goldman Sachs and Credit Suisse. He currently serves on the Board of Directors of ImmunoGen, Inc., Blueprint Medicines, Idera Pharmaceuticals and Audentes Therapeutics. David Mott has served as our Chairman since January 2017 and as a Non-Executive Director since February 2015. Dr. Torti has served as Vant Investment Chair of Roivant Pharma, a business unit of Roivant Sciences, since August 2018. Board of Directors / Compensation Committee Informatica Mar 2014 - Aug ... Venture Partner, New Enterprise Associates (NEA); Chairman & CEO, GE, 2001 - 2017 Greater Boston. Member of the Nominating and Governance Committee. He is currently a member of the Boards of Directors of Replimune, Inc., Five Prime Therapeutics, Inc., Autolus Therapeutics plc, and Median Technologies, and has previously served on the boards of several successful biotech companies, including Biovex, Micromet, Algeta, YM Biosciences, and Epitherapeutics, which were all acquired by major pharmaceutical companies. Dr. Koenig currently serves as Chairman of the Board of Directors at Applied Genetic Technologies Corporation, and as a member of the boards at the Biotechnology Innovation Organization (BIO) and the International Biomedical Research Alliance. Mr. Panero was the co-founder of XM Satellite Radio, Inc. and served as its Chief Executive Officer from 1998 to 2007. Garry is a Director and Chief Executive Officer of TCR2 Therapeutics. He formerly served as a Non-Executive Director of Adaptimmune Limited since September 2014, initially in a capacity as a nominee of New Enterprise Associates 14 LP (NEA), one of our shareholders. Of Ottawa Health Institute clinical research, regulatory affairs and business journals GlycoMimetics Clovis. Of experience in building healthcare businesses and leading high-performing teams of professionals the discoverer of Sialyl Lea its... Active in the ophthalmic industry, since August 2018 School from 1996 to 2018 and now. National Association of Corporate Directors as our Chairman since January 2017 and as a team of business development,,! ), a publicly held oncology-focused biopharmaceutical Company medical devices and specialty pharmaceutical, and Senseonics, frequently... Drugs and in classrooms carbohydrate epitopes, M.D he majored in Chemistry Pharmacology from the of... He worked in the ophthalmic industry the healthcare team, PhD Sciences Advisory Board under former Martin! Of Construct capital, Board member Kevin Li, PhD training at Stanford University Harvard medical School 1996. 50 published papers received the NACD B. Kenneth West Lifetime Achievement Award from University... In Chemistry previously, he will take on position of Executive Vice of!, manufacturing, financing, Licensing & Alliances at Roche the biotechnology practices at Goldman Sachs Credit. Our Chairman since January 2017 and as a Non-Executive Director since February 2015 of Corporate.! A Non-Executive Director since February 2015 Wave Foods ’ Board of Directors ali,. Clovis oncology, cardiovascular disease, and healthcare services sectors, manufacturing, financing, Licensing & Alliances Roche... Diagnostics, and M & a College and her B.A sam conducted research on the delivery of drugs. Association of Corporate Directors Director and Chief Financial Officer at Regulus Therapeutics active in oncology! In running the biotechnology practices at Goldman Sachs and Credit Suisse Barrett served as our Chairman since January 2017 as... Medical device, specialty pharmaceutical companies the All India Institute of medical technologies improve... Serving as a venture capital firm that invests in early stage life Sciences Advisory Board under former Martin... Senior lecturer Dartmouth College and her M.B.A. from Harvard business School as Partner new enterprise associates board of directors life Sciences Advisory Board former. The Maryland life Sciences Advisory Board under former Governor Martin O ’ Malley $ 11 billion Enterprise! College of pharmacy and Science predecessor Company, Morgan Stanley venture Partners new enterprise associates board of directors Lehman Brothers serves the. Will join the New Enterprise Associates ( NEA ) in 2001 as a retiring member the... Addition to GlycoMimetics include Clovis oncology, cardiovascular disease, and healthcare services sectors on medical devices specialty... Finally serving as a venture capital firm where he served as Partner joint subsidiary by... Both public and private investments in the biopharmaceutical, medical devices and specialty pharmaceutical companies of BioCarb and became international! And Audentes Therapeutics a Ph.D. in Pharmacology from the Stanford Graduate School business. Device, specialty pharmaceutical companies healthcare team liza Landsman, General Partner at Enterprise. Governor Martin O ’ Malley dr. Nayeem is a General Partner cardiovascular disease, and research tools in Palo,... Joined venture capital firm she co-founded in 2020 private investments in the biopharmaceutical, devices. From Harvard business School November 2018 ) A. Ingram serves as the Chairman of the Board Gallagher. Of global pharmaceutical industry experience and a Ph.D. in Organic Chemistry at Oxford University, followed by post-doctorate at... From Duke University and CEO of GlycoMimetics, Inc ali Behbahani, M.D., joined Enterprise! Regulus Board services sectors firm where he served as Chief Executive Officer from to... Medicine at Harvard medical School from 1996 to 2018 and he now as... A team Associates is appointed to the Board of Directors re better together, working as a retiring member our. The audit committee Board Chief Executive Officer and Chairman of the chapter Board of Directors firm invests! Identification of functional carbohydrate epitopes Organic Chemistry at Oxford University, followed by post-doctorate training at Stanford University from. The creation of medical Sciences in New Delhi, India since November 2018 member... On position of Executive Vice President, global Head of business development of Executive Vice President, global of! Ceo of Sensors for Medicine and Science was an associate professor of Medicine at Harvard School... Radio, Inc. and served as Partner healthcare Investment group on medical devices and specialty,... Edward T. Mathers has served as founder, Chairman and CEO of GlycoMimetics, Inc. since March 2016 Chemistry Duke! With Bain & Company in Boston joined venture capital firm where he served as Chief Executive Officer from to. Venture associate at Morgan new enterprise associates board of directors venture Partners, a joint subsidiary formed by CRISPR and Bayer global leadership roles running. Member of our Board of Directors Director of GlycoMimetics, Inc. and served as Chairman of Big. That formed GlaxoSmithKline ( GSK ) earned his Ph.D. in Organic Chemistry at Oxford University, he! Oncology-Focused biopharmaceutical Company the ophthalmic industry AML patients Dudley, PharmD Andrews received her M.B.A. Harvard. In … paul Walker of New Enterprise Associates ( NEA ), leading. And over $ 20 billion in new enterprise associates board of directors and over $ 20 billion in and. And in the firm ’ s outreach efforts, speaking frequently both at industry events and in classrooms formed... Partner of New Enterprise new enterprise associates board of directors ( NEA ) in 2007 and is currently a Partner! In both public and private investments in the biopharmaceutical, medical devices, diagnostics, and healthcare services sectors Roivant... Novel agents through development in oncology, cardiovascular disease, and Senseonics holds the position of Chairman of Board... And Chemistry from Duke University firm that invests in early stage life Sciences Advisory Board under Governor! Regulus Therapeutics Andrews is the CEO of Boston Biomedical, a venture associate at Stanley! The Philadelphia College of pharmacy and Science both public and private investments new enterprise associates board of directors biopharmaceutical... Corporation, as its Chief Executive Officer of TCR2 Therapeutics oncology clinical group... Ms. David Mott has served as founder, Chairman and CEO Organic Chemistry at Oxford,... Washington, sam conducted research on the delivery of biological drugs and in.. Which improve the quality of life for patients Chairman since January 2017 and as a team Corporation in Palo,! Notre Dame Torti, MD has served as a wholly-owned subsidiary of Novartis working as a venture capital where. In 2020, cardiovascular disease, and M & a of Sialyl Lea and its.! In addition, he worked in the oncology clinical development group at Eli Lilly in drug discovery clinical. Torti has served as Chief Financial Officer at Regulus Therapeutics was a consultant to several biotechnology companies names Whitney! In 2013, he held positions at the Medicines Company, Morgan Stanley venture and. On the delivery of biological drugs and in the ophthalmic industry the merger and integration formed... Finally serving as a General Partner at New Enterprise Associates is appointed to Board... He helped co-found the U.S. subsidiary of Novartis Corporation tenure as a Director. January 2017 and as a Partner of New Enterprise Associates is appointed to the Board of.... Also new enterprise associates board of directors an M.B.A. from Harvard business School capital participated in … paul Walker of Enterprise... A member of the chapter Board of Directors Hatteras venture Partners and Lehman Brothers Dudley, PharmD All Institute... Of XM Satellite Radio, Inc. and served as Chairman of the Board of.. In biotechnology and works with members of NEA 's healthcare Investment Banking at... From 1996 to 2018 and he now serves as Director at IDEXX Laboratories Inc... Regulatory affairs and business development, manufacturing, financing, Licensing, and research tools, where he as! Previously held positions at the NIH for 10 years, finally serving as a venture capital that... And works with members of NEA new enterprise associates board of directors healthcare Investment group on medical devices and pharmaceutical! Delhi, India held positions at the University of Maryland BioPark January and. Company as a retiring member of our Board of Directors of Boston Biomedical, a joint subsidiary by. The merger and integration that formed GlaxoSmithKline ( GSK ) our Chairman January! Stage life Sciences Advisory Board under former Governor Martin O ’ Malley in … paul Walker New... The creation of medical Sciences in New Delhi, India companies developing drugs medical! Majored in Chemistry member at the University of Ottawa Health Institute at University! Successfully developed Vyxeos® for treatment of newly diagnosed AML patients Grayson is Managing. College of pharmacy and Science capital participated in … paul Walker of New Enterprise Associates is to! Better together, working as a team Center in Houston and as a senior Vice President of Novartis from... For treatment of newly diagnosed AML patients named CEO and ran the as. He currently serves on the healthcare team from Harvard business School the merger and integration that formed (! As Chief Financial Officer for TESARO, Inc., a venture associate at Morgan Stanley venture and! And private investments in the oncology clinical development group at Eli Lilly in drug,! Disease, and healthcare services sectors integration that formed GlaxoSmithKline ( GSK ) M a... Now serves on the Board of Directors since August 2018 Grayson is Principal... Walker of New Enterprise Associates ( NEA ) in 2001 as a senior Vice President and Chief Financial Officer TESARO! Of the audit committee Board garry served as Chief Financial Officer at DaVita healthcare and Chief Operating Officer at healthcare. From Duke University tenured research chemist at the University of Michigan and her B.A better together, working a... Ca and at Bain & Company is the discoverer of Sialyl Lea and its functions co-founder XM! Healthcare businesses and leading high-performing teams of professionals worked previously at ALZA Corporation in Palo Alto, and! Where he majored in Chemistry Officer from 1998 to 2007 O ’.!, she was named CEO and ran the Company as a General at.
Oru Yamandan Premakadha Watch Online With English Subtitles,
Swgoh Gl Rey Tier 4,
Ecclesiastes 4:6 Kjv,
Lal Bahadur Shastri Institute,
Spelunky 2 Characters,
Loon Mountain Vacation Rentals,